Evaluation and Treatment of Adult Growth Hormone Deficiency: An Endocrine Society Clinical Practice Guideline
The DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
OBJECTIVE The aim was to update The Endocrine Society Clinical Practice Guideline on Evaluation and Treatment of Adult Growth Hormone Deficiency (GHD) previously published in 2006. CONSENSUS PROCESS Consensus was guided by systematic reviews of evidence and discussions through a series of conference calls and e-mails. An initial draft was prepared by the Task Force, with the help of a medical writer, and reviewed and commented on by members of The Endocrine Society. A second draft was reviewed and approved by The Endocrine Society Council. At each stage of review, the Task Force received written comments and incorporated substantive changes. CONCLUSIONS GHD can persist from childhood or be newly acquired. Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood. GH therapy offers benefits in body composition, exercise capacity, skeletal integrity, and quality of life measures and is most likely to benefit those patients who have more severe GHD. The risks associated with GH treatment are low. GH dosing regimens should be individualized. The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GHD in particular has a wide range of test methodology and diagnostic thresholds employed across studies, despite agreement among global guidelines [26 · , 64-67] as to what constitutes deficiency.”
From Neuroendocrine Disruptions Following Head Injury (2023) · cites this paper as [65]
In the citing paper
“For the diagnosis of TBI-induced GHD, the ITT and the GHRHϩARG test are now considered as the tests of choice with similar accuracy (194,215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“The glucagon stimulation test (GST) (1 mg glucagon im, GH measurements every 30 min until 240 min after administration) has been proposed as an alternative diagnostic because it is able to differentiate between GH-deficient and healthy subjects with a sensitivity and specificity of 100% if a peak GH of 3 g/L is considered (215, 226).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“For the ITT, peak GH response levels lower than 3 g/L indicate severe GHD in adults (if hypoglycemia is adequately reached) (194,215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
In the citing paper
“Therefore, in the latest Endocrine Society guideline on the evaluation and treatment of adult GHD, as part of their standard clinical care, patients with severe GHD (diagnosed by appropriate dynamic tests and with relevant clinical features) were recommended individualized physiological doses of recombinant GH treatment (215).”
From Pituitary Dysfunction After Traumatic Brain Injury: A Clinical and Pathophysiological Approach (2015) · cites this paper as [215]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Items 201–207 of 207
Pituitary Gene Mutations and the Growth Hormone Pathway
Moseley, C. T., & Phillips, J. A., III (2000) · Seminars in Reproductive Medicine · doi:10.1055/s-2000-13473 · Cited by 14
Comment on Growth Hormone Therapy and Retinal Changes Mimicking Diabetic Retinopathy
Radetti, G., Gentili, L., & Lepidi, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6415-1 · Cited by 10
Cho, G., Jeong, I., Kim, S. H., Kim, M.-K., Park, W.-J., Oh, D.-J., & Yoo, H.-J. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.051 · Cited by 10
Skeletal requirements for optimal growth hormone replacement in the transitional years
Mukherjee, A., Attanasio, A. F., & Shalet, S. M. (2003) · Growth Hormone & IGF Research · doi:10.1016/s1096-6374(03)00069-8 · Cited by 8
Badre-Esfahani, S. K., Nellemann, B., Danielsen, D. H., Fisker, S., Christiansen, J. S., & Jørgensen, J. O. L. (2007) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2007.01.012 · Cited by 4
Comment on Growth Hormone Therapy and Retinal Changes Mimicking Diabetic Retinopathy1
Koller, E. A., Green, L., & Malozowski, S. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.2.6415-2 · Cited by 3
Self-citationEmpty sella in children and adolescents with possible hypothalamic- pituitary disorders
Cacciari, E., Zucchini, S., Ambrosetto, P., Tani, G., Carlà, G., Cicognani, A., Pirazzoli, P., Sganga, T., Balsamo, A., & Cassio, A. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.78.3.8126155 · Cited by 2
Cited by
Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline
Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1818 · Cited by 1,270
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945
Growth Hormone, Insulin-Like Growth Factors, and the Skeleton
Giustina, A., Mazziotti, G., & Canalis, E. (2008) · Endocrine Reviews · doi:10.1210/er.2007-0036 · Cited by 914
Grimberg, A., DiVall, S. A., Polychronakos, C., Allen, D. B., Cohen, L. E., Quintos, J. B., Rossi, W. C., Feudtner, C., Murad, M. H., & on behalf of the Drug and Therapeutics Committee and Ethics Committee of the Pediatric Endocrine Society (2016) · Hormone Research in Paediatrics · doi:10.1159/000452150 · Cited by 697
Lipshultz, S. E., Adams, M. J., Colan, S. D., Constine, L. S., Herman, E. H., Hsu, D. T., Hudson, M. M., Kremer, L. C., Landy, D. C., Miller, T. L., et al. (2013) · Circulation · doi:10.1161/cir.0b013e3182a88099 · Cited by 612
Metadata
- Authors
- Molitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L.
- Affiliations
- Northwestern University (US)
- University of North Carolina at Chapel Hill (US)
- University of Washington (US)
- University of Virginia (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2011-06
- Volume
- 96
- Issue
- 6
- Pages
- 1587-1609
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2090627812
- Semantic Scholar
- 82180f0f73f275a6a0e865c2c46af465e9dc1fc8
- Cited by
- 1,047
- References
- 207
- Citations by year
- 2026: 31 · 2025: 43 · 2024: 46 · 2023: 53 · 2022: 59 · 2021: 61 · 2020: 59 · 2019: 59 · 2018: 64 · 2017: 56 · 2016: 66 · 2015: 63 · 2014: 61 · 2013: 75 · 2012: 42
- FWCI
- 57.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- adult growth hormone deficiency, growth hormone therapy, body composition, exercise capacity, skeletal integrity, quality of life, treatment risks and benefits
- MeSH terms
- Adult, Dwarfism, Pituitary, Humans, Evidence-Based Medicine, Human Growth Hormone, Hormone Replacement Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.